pipeline-prospector-insert-v1
X

Find Approved Drugs for Cardiology/Vascular Diseases in Clinical Development in UNITED KINGDOM

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Propranolol

            Therapeutic Area: Cardiology/Vascular Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Atnahs Pharma

            Deal Size: $390 million Upfront Cash: $350 million

            Deal Type: Divestment January 27, 2020

            Details:

            AstraZeneca is seeking $350 million from Atnahs Pharma for global trade rights to a series of five hypertension drugs off-patent: Inderal, Tenormin, Tenoretic, Zestril and Zestoretic.